Results 1 to 10 of about 24,552 (280)

Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment-Naive Chronic Lymphocytic Leukemia: A Real-World Propensity Score-Matched Study. [PDF]

Cancer Med
In a real‐world matched cohort study of treatment‐naïve TP53 wild‐type CLL patients, venetoclax plus obinutuzumab demonstrated significantly longer time to next treatment and improved 4‐year overall survival compared to first‐line acalabrutinib. Despite higher rates of cytopenias and infections, the venetoclax‐based regimen showed superior efficacy ...
Liao PW, Ko BS, Su YC, Chao WT, Teng CJ.
europepmc   +2 more sources

Case Report: A case series of using whole exome sequencing to detect novel variants in Vietnamese patients with inborn errors of immunity. [PDF]

Front Genet
Kim Lien NT, Van Tung N, Minh Huong LT, Van Anh NT, Phuong Mai NT, Dien TM, Hien NT, Tao NT, Hoang NH.   +8 more
europepmc   +1 more source

B cell receptor signaling in autoimmune rheumatic diseases: regulatory mechanisms and therapeutic targeting. [PDF]

Front Immunol
Zhu Y, Gao L, Han Y, Liu F, Xie X, Dai X, Wang Y, Guo Y, Luo C, Chen Y, Huang P, Du Z.   +11 more
europepmc   +1 more source

Latest advances in frontline CLL treatment from the 2025 ASH congress. [PDF]

Ann Hematol
Visentin A.
europepmc   +1 more source

eLife assessment: Conformational heterogeneity of the BTK PHTH domain drives multiple regulatory states

Jonathan A. Cooper
openalex   +1 more source

Btk inhibition: the importance of being selective

Blood Advances
openaire   +2 more sources

On-Target BTK Mutations Promote Resistance to Noncovalent BTK Inhibitors

Cancer Discovery, 2022
Abstract Resistance to noncovalent BTK inhibitors is mediated by non-C481 BTK and PLCγ2 mutations.
openaire   +2 more sources